BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15623644)

  • 1. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
    Post DE; Devi NS; Li Z; Brat DJ; Kaur B; Nicholson A; Olson JJ; Zhang Z; Van Meir EG
    Clin Cancer Res; 2004 Dec; 10(24):8603-12. PubMed ID: 15623644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.
    Post DE; Van Meir EG
    Oncogene; 2003 Apr; 22(14):2065-72. PubMed ID: 12687009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.
    Post DE; Sandberg EM; Kyle MM; Devi NS; Brat DJ; Xu Z; Tighiouart M; Van Meir EG
    Cancer Res; 2007 Jul; 67(14):6872-81. PubMed ID: 17638898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
    Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
    Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
    Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
    Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
    Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
    Holzmüller R; Mantwill K; Haczek C; Rognoni E; Anton M; Kasajima A; Weichert W; Treue D; Lage H; Schuster T; Schlegel J; Gänsbacher B; Holm PS
    Int J Cancer; 2011 Sep; 129(5):1265-76. PubMed ID: 21710499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.
    Pipiya T; Sauthoff H; Huang YQ; Chang B; Cheng J; Heitner S; Chen S; Rom WN; Hay JG
    Gene Ther; 2005 Jun; 12(11):911-7. PubMed ID: 15690061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
    Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD
    Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
    Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
    Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.